Skip to content
value.today

Cell Source, Inc.: peers

Change the peers

Cell Source, Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Cell Source, Inc., Zivo Bioscience Inc., Reviva Pharmaceuticals Holdings, Inc., Sigyn Therapeutics, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Cell Source, Inc., Zivo Bioscience Inc., Karyopharm Therapeutics Inc., Seres Therapeutics, Inc., Black Hawk Acquisition Corporation, Aytu Bioscience, Reviva Pharmaceuticals Holdings, Inc., Sigyn Therapeutics, Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureCell Source, Inc.base
CLCS · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Zivo Bioscience Inc.
ZIVO · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Karyopharm Therapeutics Inc.
KPTI · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Seres Therapeutics, Inc.
MCRB · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Black Hawk Acquisition Corporation
BKHA · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Aytu Bioscience
AYTU · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Reviva Pharmaceuticals Holdings, Inc.
RVPH · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Sigyn Therapeutics, Inc.
SIGY · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$20 Mlast known, Dec 25, 2022 · Market dataLast known value: no current one3rd of 8$20 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one3rd of 8$20 MOct 30, 2026 · Market data5th of 8$20 MOct 30, 2026 · Market data6th of 8$20 MOct 30, 2026 · Market data7th of 8$21 MOct 26, 2026 · Market data2nd of 8$21 Mlast known, Mar 8, 2026 · Market dataLast known value: no current one1st of 8$19 Mlast known, Jan 7, 2022 · Market dataLast known value: no current one8th of 8$20 M8 ranked
Revenue (Better neither way: ranked highest first)——$0 MFY2024 · SEC4th of 4$146 MFY2025 · SEC1st of 4$1 MFY2025 · SEC3rd of 4——$58 MFY2026 · SEC2nd of 4————$29 M4 ranked
Net income (Higher is better)$-5 MFY2024 · SEC4th of 8$-13 MFY2024 · SEC5th of 8$-196 MFY2025 · SEC8th of 8$6 MFY2025 · SEC1st of 8$1 MFY2025 · SEC2nd of 8$-14 MFY2026 · SEC6th of 8$-20 MFY2025 · SEC7th of 8$-3 MFY2024 · SEC3rd of 8$-9 M8 ranked
Employees (Better neither way: ranked highest first)————442As on 2021 · Profile1st of 2333As on 2021 · Profile2nd of 2————————3882 ranked
Growth
Revenue growth (Higher is better)————————+0.6%FY2025 · SEC1st of 227th31st————————-13.3%FY2026 · SEC2nd of 213th9th————————-6.3%2 ranked
Revenue growth, 3 years a year (Higher is better)————————-2.4%FY2025 · SEC1st of 221st25th————————-18.8%FY2026 · SEC2nd of 28th4th————————-10.6%2 ranked
Margins and returns
Gross margin (Higher is better)————————————————————64.0%FY2026 · SEConly one with it58th78th————————64.0%—
Operating margin (Higher is better)————————-62.1%FY2025 · SEC2nd of 229th14th————————-14.4%FY2026 · SEC1st of 244th24th————————-38.3%2 ranked
Net margin (Higher is better)————————-134.2%FY2025 · SEC2nd of 220th8th————————-24.8%FY2026 · SEC1st of 240th20th————————-79.5%2 ranked
Free cash flow margin (Higher is better)————————-51.6%FY2025 · SEC2nd of 227th12th————————5.7%FY2026 · SEC1st of 263rd56th————————-23.0%2 ranked
Return on equity (Higher is better)————————————19.7%FY2025 · SEC1st of 390th84th————-52.5%FY2026 · SEC2nd of 342nd18th-419.9%FY2025 · SEC3rd of 32nd1st————-52.5%3 ranked
Valuation
P/E ratio (Better neither way: ranked highest first)————————————3.5×price Oct 30, 2026 · Market data2nd of 24th3rd14.9×price Oct 30, 2026 · Market data1st of 220th37th————————————9.2×2 ranked
Price to sales (Better neither way: ranked highest first)————————0.1×price Oct 30, 2026 · Market data3rd of 31st4th25.2×price Oct 30, 2026 · Market data1st of 386th95th————0.4×price Oct 26, 2026 · Market data2nd of 36th11th————————0.4×3 ranked
Price to book (Better neither way: ranked highest first)————————————0.5×price Oct 30, 2026 · Market data2nd of 26th6th————0.6×price Oct 26, 2026 · Market data1st of 29th9th————————0.5×2 ranked
Free cash flow yield (Higher is better)————————————4.4%price Oct 30, 2026 · Market data2nd of 284th62nd————15.7%price Oct 26, 2026 · Market data1st of 297th94th————————10.0%2 ranked
Financial strength
Debt to equity (Lower is better)————————————————————0.3×FY2026 · SEConly one with it36th27th————————0.3×—
Interest cover (Higher is better)————————————————-46.0×FY2025 · SEC2nd of 221st10th-4.4×FY2026 · SEC1st of 257th31st————————-25.2×2 ranked
Piotroski F-score (Higher is better)——————————4 of 9FY2026 · SEConly one with it————4.0 of 9—
Scorecard
Scorecard (Higher is better)0 of 6FY2024 · Scorecard6th of 80 of 7FY2024 · Scorecard6th of 85 of 18FY2025 · Scorecard4th of 88 of 14FY2025 · Scorecard1st of 83 of 6FY2025 · Scorecard2nd of 89 of 21FY2026 · Scorecard3rd of 81 of 6FY2025 · Scorecard5th of 80 of 7FY2024 · Scorecard6th of 822% passed8 ranked
Valuation checks (Higher is better)————1 of 4FY2025 · Scorecard4th of 43 of 5FY2025 · Scorecard2nd of 42 of 3FY2025 · Scorecard1st of 43 of 5FY2026 · Scorecard2nd of 4————60% passed4 ranked
Growth checks (Higher is better)0 of 2FY2024 · Scorecard4th of 70 of 2FY2024 · Scorecard4th of 72 of 6FY2025 · Scorecard2nd of 72 of 2FY2025 · Scorecard1st of 7——1 of 5FY2026 · Scorecard3rd of 70 of 1FY2025 · Scorecard4th of 70 of 2FY2024 · Scorecard4th of 70% passed7 ranked
Profitability checks (Higher is better)0 of 2FY2024 · Scorecard5th of 80 of 2FY2024 · Scorecard5th of 81 of 4FY2025 · Scorecard4th of 82 of 3FY2025 · Scorecard2nd of 81 of 1FY2025 · Scorecard1st of 82 of 5FY2026 · Scorecard3rd of 80 of 3FY2025 · Scorecard5th of 80 of 2FY2024 · Scorecard5th of 813% passed8 ranked
Financial health checks (Higher is better)0 of 1FY2024 · Scorecard5th of 80 of 2FY2024 · Scorecard5th of 81 of 3FY2025 · Scorecard3rd of 81 of 3FY2025 · Scorecard3rd of 80 of 2FY2025 · Scorecard5th of 83 of 6FY2026 · Scorecard1st of 81 of 2FY2025 · Scorecard1st of 80 of 2FY2024 · Scorecard5th of 817% passed8 ranked
Shareholder returns checks (Higher is better)0 of 1FY2024 · Scorecard1st of 50 of 1FY2024 · Scorecard1st of 50 of 1FY2025 · Scorecard1st of 50 of 1FY2025 · Scorecard1st of 5——————0 of 1FY2024 · Scorecard1st of 50% passed5 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)——0.1%2025-Q4 · 13F5th of 676.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 623.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 634.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 634.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 60.1%2026-Q2 · 13F6th of 6——28.5%6 ranked
Institutions holding (Better neither way: ranked highest first)——32025-Q4 · 13F6th of 6922026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 6402026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 6172026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 6362026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 652026-Q2 · 13F5th of 6——276 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)——+0.0 pp2025-Q4 against 2025-Q3 · 13F4th of 6+16.5 pp2026-Q2 against 2026-Q1 · 13F1st of 6-1.2 pp2026-Q2 against 2026-Q1 · 13F5th of 6+8.6 pp2026-Q2 against 2026-Q1 · 13F3rd of 6+8.9 pp2026-Q2 against 2026-Q1 · 13F2nd of 6-22.7 pp2026-Q2 against 2026-Q1 · 13F6th of 6——+4.3 pp6 ranked

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Cell Source, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Zivo Bioscience Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Karyopharm Therapeutics Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Seres Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Black Hawk Acquisition Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Aytu Bioscience: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Reviva Pharmaceuticals Holdings, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Sigyn Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Cell Source, Inc.———
Zivo Bioscience Inc.———
Karyopharm Therapeutics Inc.-62.1%FY2025
29th percentile in Healthcaremedian -7.7%, 674 companies
14th percentile in USAmedian 3.5%, 2,594 companies
Seres Therapeutics, Inc.———
Black Hawk Acquisition Corporation———
Aytu Bioscience-14.4%FY2026
44th percentile in Healthcaremedian -7.7%, 674 companies
24th percentile in USAmedian 3.5%, 2,594 companies
Reviva Pharmaceuticals Holdings, Inc.———
Sigyn Therapeutics, Inc.———

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$52 M$105 M$157 M$210 M20112013201520172019202120232025Zivo Bioscience Inc. $0 MKaryopharm Therapeutics Inc. $146 MSeres Therapeutics, Inc. $1 MAytu Bioscience $58 MSigyn Therapeutics, Inc. $0 M

Rank in the group

1st2nd3rd4th201420152016201720182019202020212022202320242025Zivo Bioscience Inc.: 4th of 4 in 2020Zivo Bioscience Inc.: 3rd of 3 in 2023Zivo Bioscience Inc.: 3rd of 3 in 2024Zivo Bioscience Inc.Karyopharm Therapeutics Inc.: 1st of 3 in 2014Karyopharm Therapeutics Inc.: 2nd of 3 in 2015Karyopharm Therapeutics Inc.: 3rd of 3 in 2016Karyopharm Therapeutics Inc.: 3rd of 4 in 2017Karyopharm Therapeutics Inc.: 1st of 4 in 2018Karyopharm Therapeutics Inc.: 1st of 4 in 2019Karyopharm Therapeutics Inc.: 1st of 4 in 2020Karyopharm Therapeutics Inc.: 1st of 3 in 2021Karyopharm Therapeutics Inc.: 1st of 3 in 2022Karyopharm Therapeutics Inc.: 1st of 3 in 2023Karyopharm Therapeutics Inc.: 1st of 3 in 2024Karyopharm Therapeutics Inc.: 1st of 3 in 2025Karyopharm Therapeutics InSeres Therapeutics, Inc.: 1st of 3 in 2016Seres Therapeutics, Inc.: 1st of 4 in 2017Seres Therapeutics, Inc.: 2nd of 4 in 2018Seres Therapeutics, Inc.: 2nd of 4 in 2019Seres Therapeutics, Inc.: 2nd of 4 in 2020Seres Therapeutics, Inc.: 2nd of 3 in 2021Seres Therapeutics, Inc.: 3rd of 3 in 2022Seres Therapeutics, Inc.: 3rd of 3 in 2025Seres Therapeutics, Inc.Aytu Bioscience: 2nd of 3 in 2014Aytu Bioscience: 1st of 3 in 2015Aytu Bioscience: 2nd of 3 in 2016Aytu Bioscience: 2nd of 4 in 2017Aytu Bioscience: 3rd of 4 in 2018Aytu Bioscience: 3rd of 4 in 2019Aytu Bioscience: 3rd of 4 in 2020Aytu Bioscience: 3rd of 3 in 2021Aytu Bioscience: 2nd of 3 in 2022Aytu Bioscience: 2nd of 3 in 2023Aytu Bioscience: 2nd of 3 in 2024Aytu Bioscience: 2nd of 3 in 2025Aytu BioscienceSigyn Therapeutics, Inc.: 3rd of 3 in 2014Sigyn Therapeutics, Inc.: 3rd of 3 in 2015Sigyn Therapeutics, Inc.: 4th of 4 in 2017Sigyn Therapeutics, Inc.: 4th of 4 in 2018Sigyn Therapeutics, Inc.: 4th of 4 in 2019Sigyn Therapeutics, Inc.
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearCell Source, Inc.Zivo Bioscience Inc.Karyopharm Therapeutics Inc.Seres Therapeutics, Inc.Black Hawk Acquisition CorporationAytu BioscienceReviva Pharmaceuticals Holdings, Inc.Sigyn Therapeutics, Inc.
2026—————$58 MSEC——
2025——$146 MSEC1st$1 MSEC3rd—$66 MSEC2nd——
2024—$0 MSEC3rd$145 MSEC1st——$65 MSEC2nd——
2023—$0 MSEC3rd$146 MSEC1st——$107 MSEC2nd——
2022——$157 MSEC1st$7 MSEC3rd—$97 MSEC2nd——
2021——$210 MSEC1st$145 MSEC2nd—$66 MSEC3rd——
2020—$0 MSEC4th$108 MSEC1st$33 MSEC2nd—$28 MSEC3rd——
2019——$41 MSEC1st$35 MSEC2nd—$7 MSEC3rd—$0 MSEC4th
2018——$30 MSEC1st$28 MSEC2nd—$4 MSEC3rd—$0 MSEC4th
2017——$2 MSEC3rd$32 MSEC1st—$3 MSEC2nd—$0 MSEC4th
2016——$0 MSEC3rd$22 MSEC1st—$3 MSEC2nd——
2015——$0 MSEC2nd——$0 MSEC1st—$0 MSEC3rd

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Cell Source, Inc.#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Zivo Bioscience Inc.ZIVO · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $20 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $20 M (last known, Jul 30, 2023) · revenue $0 M (year to December 2024)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Karyopharm Therapeutics Inc.KPTI · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $20 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $20 M (Oct 30, 2026) · revenue $146 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Seres Therapeutics, Inc.MCRB · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $20 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $20 M (Oct 30, 2026) · revenue $1 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Black Hawk Acquisition CorporationBKHA · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $20 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $20 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Aytu BioscienceAYTU · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $21 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $21 M (Oct 26, 2026) · revenue $58 M (year to June 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Reviva Pharmaceuticals Holdings, Inc.RVPH · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $21 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $21 M (last known, Mar 8, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Sigyn Therapeutics, Inc.SIGY · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $19 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $19 M (last known, Jan 7, 2022)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Cocrystal Pharma, Inc.COCP · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $19 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $19 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Senti Biosciences, Inc.SNTI · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $19 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $19 M (Oct 30, 2026) · revenue $0 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • BeyondSpring Inc.BYSI · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $22 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $22 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Context Therapeutics Inc.CNTX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $22 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $22 M (Oct 27, 2026)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add
  • Lipocine Inc.LPCN · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $18 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $18 M (Oct 13, 2026) · revenue $2 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.